ArticleMolecular autism2026
Autism in neurofibromatosis type 1: prevalence, phenotype and clinical implications.
Article in Molecular autism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMonogenic conditions, such as neurofibromatosis type 1 (NF1), provide a unique opportunity to study autism within a known molecular pathway. This study estimated the prevalence of autism in a large international NF1 cohort and examined how autistic traits relate to cognitive, behavioral, and adaptive functioning.
methodsIn this cross-sectional study, 202 children with NF1 and 106 typically developing controls (aged 3-15 years) completed standardized cognitive testing and parent-reported behavioral measures. NF1 participants scoring ≥ 60 on the Social Responsiveness Scale-2 were evaluated using the Autism Diagnostic Observation Schedule-2 and Autism Diagnostic Interview-Revised, with DSM-5-TR autism diagnoses established by multidisciplinary consensus. Neurodevelopmental profiles were compared across NF1 subgroups (autism, broader autistic traits, no-autistic-traits) and controls.
resultsAutistic traits were elevated and continuously distributed in NF1. An estimated 28% (95%CI: 21.7%-34.3%) met DSM-5-TR criteria for autism and 22% exhibited a broader autistic phenotype, with comparable rates in males and females. Children classified as autistic and those with broader autistic traits showed similarly marked behavioral and adaptive challenges, whereas NF1 children without autistic traits showed milder difficulties. Findings establish NF1 as a condition in which autism is common and clinically significant. Autistic features in NF1 occur across the cognitive spectrum and are accompanied by overlapping behavioral and functional impairments that challenge categorical diagnostic boundaries. LIMITATIONS: The cross-sectional design precludes conclusions about developmental trajectories. The absence of genotype data prevented exploration of genotype-phenotype correlations and the influence of polygenic risk factors outside the NF1 locus.
conclusionsFindings provide strong support for routine, early screening for autism in NF1 and the recognition that subthreshold traits can be similarly impairing. NF1 provides a powerful model for investigating how a monogenic condition contributes to diverse neurodevelopmental profiles and informs precision-medicine approaches in autism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.